Esperion Starts Next Phase Of Cholesterol Drug TrialThe Plymouth pharma startup Esperion Therapeutics Inc. (Nasdaq: ESPR), Wednesday announced the first patient in a Phase 2b clinical study had received the first dose of ETC-1002, its lead anti-cholesterol drug.

More From CBS Detroit

Guide: Last Minute Valentine's Day IdeasYou've got less than a week to plan the most romantic night of the year. Better get going!
Best Places To Get A Hot Toddy
Best Sledding Hills

Watch & Listen